(Q38121574)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855299%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855299%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

0 references

0 references

non-alcoholic steatohepatitis

1 reference

based on heuristic

inferred from title

publication date

1 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855299%20AND%20SRC:MED&resulttype=core&format=json

Journal of Gastroenterology and Hepatology

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855299%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

28 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855299%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

68-76

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23855299%20AND%20SRC:MED&resulttype=core&format=json

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

5 March 2020

cites work

1 reference

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

21 January 2018

1 reference

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

Nonalcoholic fatty liver disease in lean individuals in the United States

21 January 2018

1 reference

Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground

21 January 2018

1 reference

Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease

21 January 2018

1 reference

NAFLD in Asia--as common and important as in the West

21 January 2018

1 reference

Epidemiology and natural history of non-alcoholic steatohepatitis

21 January 2018

1 reference

Incidence and natural course of fatty liver in the general population: the Dionysos study.

21 January 2018

1 reference

Epidemiology and natural history of patients with NAFLD.

21 January 2018

1 reference

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

21 January 2018

1 reference

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

21 January 2018

1 reference

Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease

21 January 2018

1 reference

Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease.

21 January 2018

1 reference

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

Identification and characterization of metabolically benign obesity in humans

21 January 2018

1 reference

Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review

21 January 2018

1 reference

Hepatocellular carcinoma in cirrhosis: incidence and risk factors

21 January 2018

1 reference

Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis

21 January 2018

1 reference

LXRs regulate the balance between fat storage and oxidation.

21 January 2018

1 reference

Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites

21 January 2018

1 reference

Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools

21 January 2018

1 reference

Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes

21 January 2018

1 reference

Diabetes and apoptosis: liver

21 January 2018

1 reference

Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice.

21 January 2018

1 reference

Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms.

21 January 2018

1 reference

Toll-like receptor-4 mediates obesity-induced non-alcoholic steatohepatitis through activation of X-box binding protein-1 in mice.

21 January 2018

1 reference

A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells.

21 January 2018

1 reference

Germ-free C57BL/6J mice are resistant to high-fat-diet-induced insulin resistance and have altered cholesterol metabolism.

21 January 2018

1 reference

Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.

21 January 2018

1 reference

Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease.

21 January 2018

1 reference

Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome

21 January 2018

1 reference

Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease

21 January 2018

1 reference

PNPLA3, a genetic marker of progressive liver disease, still hiding its metabolic function?

21 January 2018

1 reference

Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase

21 January 2018

1 reference

Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis

21 January 2018

1 reference

Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic

21 January 2018

1 reference

Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease.

21 January 2018

1 reference

Can NASH be diagnosed, graded, and staged noninvasively?

21 January 2018

1 reference

Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis.

21 January 2018

1 reference

Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial

21 January 2018

1 reference

The effect of lifestyle changes in non-alcoholic fatty liver disease

21 January 2018

1 reference

Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease

21 January 2018

1 reference

JNK1 but not JNK2 promotes the development of steatohepatitis in mice

21 January 2018

1 reference

Hepatocyte caspase-8 is an essential modulator of steatohepatitis in rodents

21 January 2018

1 reference

Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis.

21 January 2018

1 reference

A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

Adenosine: tipping the balance towards hepatic steatosis and fibrosis

21 January 2018

1 reference

Adenosine A(2a) receptor stimulation prevents hepatocyte lipotoxicity and non-alcoholic steatohepatitis (NASH) in rats.

21 January 2018

1 reference

Adenosine signaling contributes to ethanol-induced fatty liver in mice.

21 January 2018

1 reference

Exercise, appetite and appetite-regulating hormones: implications for food intake and weight control

21 January 2018

1 reference

Alterations in the hippocampal endocannabinoid system in diet-induced obese mice.

21 January 2018

1 reference

Incretin hormones and the satiation signal.

21 January 2018

1 reference

Combination therapy with nateglinide and vildagliptin improves postprandial metabolic derangements in Zucker fatty rats

21 January 2018

1 reference

Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity

21 January 2018

1 reference

Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet

21 January 2018

1 reference

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice

21 January 2018

1 reference

GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy

21 January 2018

1 reference

Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.

21 January 2018

1 reference

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism

21 January 2018

1 reference

Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.

21 January 2018

1 reference

Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology

21 January 2018

1 reference

Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk

21 January 2018

1 reference

Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors

21 January 2018

1 reference

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

21 January 2018

1 reference

Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms.

21 January 2018

1 reference

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis.

21 January 2018

1 reference

VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation

21 January 2018

1 reference

Lactobacillus casei Shirota protects from fructose-induced liver steatosis: a mouse model

21 January 2018

1 reference

The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance

21 January 2018

1 reference

Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference